Shopping Cart
Remove All
Your shopping cart is currently empty
CU-115 is a selective and potent TLR8 antagonist with IC50 of 1.04 µM and =>50 µM for TLR8 and TLR7, respectively. CU-115 decreases production of TNF-α and IL-1β activated by R-848 in THP-1 cells.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $53 | In Stock | In Stock | |
| 5 mg | $147 | In Stock | In Stock | |
| 10 mg | $239 | In Stock | In Stock | |
| 25 mg | $413 | In Stock | In Stock | |
| 50 mg | $579 | In Stock | In Stock | |
| 100 mg | $793 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $185 | In Stock | In Stock |
| Description | CU-115 is a selective and potent TLR8 antagonist with IC50 of 1.04 µM and =>50 µM for TLR8 and TLR7, respectively. CU-115 decreases production of TNF-α and IL-1β activated by R-848 in THP-1 cells. |
| Targets&IC50 | TLR8:1.04 μM, TLR7:50 μM |
| In vitro | CU-115 (1, 5, and 20 µM) inhibits TLR9 to 10-25% inhibition. CU-115 (5-20 µM) inhibits increases in the activity of type I IFN transcriptional induced by the ssRNA nucleic acid ligands 3p-hpRNA or G3-YSD. CU-115 (5-20 µM) abolishes the TNF-α production activated by R848 (1 µg/ml) and represses the expression of IL-1β in hTHP-1 cells. CU-115 does not modulate the NF-kB inhibition induced by Pam2CSK4, Pam3CSK4, LPS, R848, Poly(I:C), and Flic in HEK-293 TLR1/2, TLR2/6, TLR3, and TLR4 cells[1]. |
| Synonyms | N-(4-(3,5-bis(trifluoromethyl)phenoxy)phenyl)-2-fluoro-6-iodobenzamide |
| Molecular Weight | 569.21 |
| Formula | C21H11F7INO2 |
| Cas No. | 2471982-20-2 |
| Smiles | Fc1cccc(I)c1C(=O)Nc1ccc(Oc2cc(cc(c2)C(F)(F)F)C(F)(F)F)cc1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (79.06 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 2 mg/mL (3.51 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.